Amgen Shares Slide 1.3% with $510M Daily Volume Ranking 178th as Strategic Challenges Weigh on Biopharma Giant

On August 18, 2025, Amgen (AMGN) closed with a 1.30% decline, trading at a daily volume of $0.51 billion, which ranked 178th among stocks listed on U.S. exchanges. The biopharmaceutical giant's shares underperformed broader market benchmarks, reflecting mixed investor sentiment amid ongoing regulatory scrutiny and competitive pressures in its key therapeutic areas.

Recent developments highlighted Amgen's strategic challenges in maintaining market dominance. A pending FDA advisory panel meeting on its next-generation cholesterol drug evoked cautious trading behavior, while analysts noted increased pricing pressure from generic entrants in its core biosimilars portfolio. Institutional investors adjusted position sizes in response to evolving macroeconomic signals, though no major corporate announcements directly impacting valuation metrics were reported during the period.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day resulted in a moderate return. The total profit from this strategy, considering the given time frame from 2022 to the present, is $2,340. The cumulative return reaches 23.4%. This indicates a positive performance, but the returns are not significantly high, suggesting a more conservative approach to trading volume-based strategies.